Real-time internet of medical things framework for early detection of Covid-19

Engineered two-dimensional nanomaterials based diagnostics integrated with internet of medical things (IoMT) for COVID-19

More than four years have passed since an inimitable coronavirus disease (COVID-19) pandemic hit the globe in 2019 after an uncontrolled transmission of the severe acute respiratory syndrome (SARS-CoV-2) infection. The occurrence of this highly contagious respiratory infectious disease led to chaos and mortality all over the world. The peak paradigm shift of the researchers was inclined towards the accurate and rapid detection of diseases. Since 2019, there has been a boost in the diagnostics of COVID-19 via numerous conventional diagnostic tools like RT-PCR, ELISA, etc., and advanced biosensing kits like LFIA, etc. For the same reason, the use of nanotechnology and two-dimensional nanomaterials (2DNMs) has aided in the fabrication of efficient diagnostic tools to combat COVID-19. This article discusses the engineering techniques utilized for fabricating chemically active E2DNMs that are exceptionally thin and irregular. The techniques encompass the introduction of heteroatoms, intercalation of ions, and the design of strain and defects. E2DNMs possess unique characteristics, including a substantial surface area and controllable electrical, optical, and bioactive properties. These characteristics enable the development of sophisticated diagnostic platforms for real-time biosensors with exceptional sensitivity in detecting SARS-CoV-2. Integrating the Internet of Medical Things (IoMT) with these E2DNMs-based advanced diagnostics has led to the development of portable, real-time, scalable, more accurate, and cost-effective SARS-CoV-2 diagnostic platforms. These diagnostic platforms have the potential to revolutionize SARS-CoV-2 diagnosis by making it faster, easier, and more accessible to people worldwide, thus making them ideal for resource-limited settings. These advanced IoMT diagnostic platforms may help with combating SARS-CoV-2 as well as tracking and predicting the spread of future pandemics, ultimately saving lives and mitigating their impact on global health systems.

A brief review and scientometric analysis on ensemble learning methods for handling COVID-19

Numerous efforts and research have been conducted worldwide to combat the coronavirus disease 2019 (COVID-19) pandemic. In this regard, some researchers have focused on deep and machine-learning approaches to discover more about this disease. There have been many articles on using ensemble learning methods for COVID-19 detection. Still, there seems to be no scientometric analysis or a brief review of these researches. Hence, a combined method of scientometric analysis and brief review was used to study the published articles that employed an ensemble learning approach to detect COVID-19. This research used both methods to overcome their limitations, leading to enhanced and reliable outcomes. The related articles were retrieved from the Scopus database. Then a two-step procedure was employed. A concise review of the collected articles was conducted. Then they underwent scientometric and bibliometric analyses. The findings revealed that convolutional neural network (CNN) is the mostly employed algorithm, while support vector machine (SVM), random forest, Resnet, DenseNet, and visual geometry group (VGG) were also frequently used. Additionally, China has had a significant presence in the numerous top-ranking categories of this field of research. Both study phases yielded valuable results and rankings.

Prognosis of COVID-19 patients using lab tests: A data mining approach

Background

The rapid prevalence of coronavirus disease 2019 (COVID-19) has caused a pandemic worldwide and affected the lives of millions. The potential fatality of the disease has led to global public health concerns. Apart from clinical practice, artificial intelligence (AI) has provided a new model for the early diagnosis and prediction of disease based on machine learning (ML) algorithms. In this study, we aimed to make a prediction model for the prognosis of COVID-19 patients using data mining techniques.

Methods

In this study, a data set was obtained from the intelligent management system repository of 19 hospitals at Shahid Beheshti University of Medical Sciences in Iran. All patients admitted had shown positive polymerase chain reaction (PCR) test results. They were hospitalized between February 19 and May 12 in 2020, which were investigated in this study. The extracted data set has 8621 data instances. The data include demographic information and results of 16 laboratory tests. In the first stage, preprocessing was performed on the data. Then, among 15 laboratory tests, four of them were selected. The models were created based on seven data mining algorithms, and finally, the performances of the models were compared with each other.

Results

Based on our results, the Random Forest (RF) and Gradient Boosted Trees models were known as the most efficient methods, with the highest accuracy percentage of 86.45% and 84.80%, respectively. In contrast, the Decision Tree exhibited the least accuracy (75.43%) among the seven models.

Conclusion

Data mining methods have the potential to be used for predicting outcomes of COVID-19 patients with the use of lab tests and demographic features. After validating these methods, they could be implemented in clinical decision support systems for better management and providing care to severe COVID-19 patients.

Enhanced Patient-Centricity: How the Biopharmaceutical Industry Is Optimizing Patient Care through AI/ML/DL

Technologies utilizing cutting-edge methodologies, including artificial intelligence (AI), machine learning (ML) and deep learning (DL), present powerful opportunities to help evaluate, predict, and improve patient outcomes by drawing insights from real-world data (RWD) generated during medical care. They played a role during and following the Coronavirus Disease 2019 (COVID-19) pandemic by helping protect healthcare providers, prioritize care for vulnerable populations, predict disease trends, and find optimal therapies. Potential applications across therapeutic areas include diagnosis, disease management and patient journey mapping. Use of fit-for-purpose datasets for ML models is seeing growth and may potentially help additional enterprises develop AI strategies. However, biopharmaceutical companies often face specific challenges, including multi-setting data, system interoperability, data governance, and patient privacy requirements. There remains a need for evolving regulatory frameworks, operating models, and data governance to enable further developments and additional research. We explore recent literature and examine the hurdles faced by researchers in the biopharmaceutical industry to fully realize the promise of AI/ML/DL for patient-centric purposes.